Alexandria Real Estate Equities, Inc. an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Mega campus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of December 31, 2025, Alexandria has a total market capitalization of $20.75 billion and an asset base in North America that includes 35.9 million RSF of operating properties and 3.5 million RSF of Class A/A+ properties undergoing construction. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Mega campus environments that enhance our tenant ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Alexandria Real Estate Equities (ARE) reported trailing twelve months (TTM) revenue of $3.03B as of December 2025, which represents a 2.9% decrease year-over-year. The company's operating margin has contracted to 22.8% from 23.5% a year ago. In terms of profitability, ARE reported a net loss of $1.43B. Valuation-wise, the stock trades at a Price-to-Sales (P/S) ratio of 2.8x. The company generated $0 in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages